Towards developing biomarkers for glioblastoma multiforme: a proteomics view

References

• DeAngelis LM. Brain tumors. N Engl J Med 2001;344(2):114-23
   PubMed Web of Science ®Google Scholar
• Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15(11):1311-33
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Paving new pathways. Nat Med 2002;8(9):938-40
   Google Scholar
• Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008;105(2):287-95
   Google Scholar
• Westermark B. Glioblastoma--a moving target. Ups J Med Sci 2012;117(2):251-6
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21(21):2683-710
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-73
   PubMed Web of Science ®Google Scholar
• Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006;66(23):11502-13
   PubMed Web of Science ®Google Scholar
• Sanai N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. World Neurosurg 2010;74(1):4-5
   Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
   PubMed Web of Science ®Google Scholar
• Chin L, Meyerson M. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol 2004;31(5):595-604
   Google Scholar
• Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2013;61(1):25-41
   PubMed Web of Science ®Google Scholar
• Riddick G, Fine HA. Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 2011;7(8):439-50
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013;110(10):4009-14
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Preusser M. Circulating biomarkers of CNS tumors: an update. Biomark Med 2013;7(2):267-85
   PubMed Web of Science ®Google Scholar
• Kalinina J, Peng J, Ritchie JC, Van Meir EG. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011;13(9):926-42
   PubMed Web of Science ®Google Scholar
• Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009;9(7):695-707
   Web of Science ®Google Scholar
• Sirdeshmukh R, Santosh V, Srikanth A. Differential protein expression, protein profiles of human gliomas and clinical implications. In: Appasani K, editor. Bio arrays: from basics to diagnostics. Humana Press; Totowa, NJ, USA: 2006. p. 145-69
   Google Scholar
• Gupta MK, Polisetty RV, Ramamoorthy K, et al. Secretome analysis of Glioblastoma cell line--HNGC-2. Mol Biosyst 2013;9(6):1390-400
   Google Scholar
• Polisetty RV, Gupta MK, Nair SC, et al. Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J Proteomics 2011;74(10):1918-25
   Google Scholar
• Weeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, et al. Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. Talanta 2012;99:294-301
   PubMed Web of Science ®Google Scholar
• Mathivanan S, Lim JW, Tauro BJ, et al. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 2010;9(2):197-208
   PubMed Web of Science ®Google Scholar
• Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 2012;18(12):1835-40
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Kalra H, Mathivanan S. ExoCarta as a resource for exosomal research. J Extracell Vesicles 2012;1
   PubMedGoogle Scholar
• Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3(12):1154-69
   PubMed Web of Science ®Google Scholar
• Gautam P, Nair SC, Gupta MK, et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS ONE 2012;7(9):e46153
   PubMed Web of Science ®Google Scholar
• Gollapalli K, Ray S, Srivastava R, et al. Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 2012;12(14):2378-90
   PubMed Web of Science ®Google Scholar
• Lin Q, Tan HT, Lim HS, Chung MC. Sieving through the cancer secretome. Biochim Biophys Acta 2013;1834(11):2360-71
   PubMed Web of Science ®Google Scholar
• Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl 2013;7(5-6):355-66
   PubMed Web of Science ®Google Scholar
• James A, Jorgensen C. Basic design of MRM assays for peptide quantification. Methods Mol Biol 2010;658:167-85
   PubMedGoogle Scholar
• Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5(10):782-92
   PubMed Web of Science ®Google Scholar
• Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 2002;1(13):1229-36
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
   PubMed Web of Science ®Google Scholar
• Dong H, Luo L, Hong S, et al. Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC Syst Biol 2010;4:163
   PubMed Web of Science ®Google Scholar
• Polisetty RV, Gautam P, Sharma R, et al. LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics 2012;11(6):M111 013565
   Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505(7484):495-501
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87(21):8602-6
   PubMed Web of Science ®Google Scholar
• Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 2013;280(21):5350-70
   PubMed Web of Science ®Google Scholar
• Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63(11):2742-6
   PubMed Web of Science ®Google Scholar
• Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 2012;31(36):4054-66
   PubMedGoogle Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim SH, Cho J, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012;84(3):661-7
   Google Scholar
• Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses 2013;80(6):728-31
   Google Scholar
• Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014. [Epub ahead of print]
   Google Scholar
• Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81(17):1515-22
   PubMed Web of Science ®Google Scholar
• Cho WC. Circulating microRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front Genet 2011;2:7
   PubMedGoogle Scholar
• Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42(8):1273-81
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6(3):e17438
   PubMed Web of Science ®Google Scholar
• Karsy M, Arslan E, Moy F. Current progress on understanding MicroRNAs in glioblastoma multiforme. Genes Cancer 2012;3(1):3-15
   PubMedGoogle Scholar
• Sana J, Hajduch M, Michalek J, et al. MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med 2011;15(8):1636-44
   Google Scholar
• Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 2012;21(10):1475-88
   PubMed Web of Science ®Google Scholar
• Moller HG, Rasmussen AP, Andersen HH, et al. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 2013;47(1):131-44
   PubMed Web of Science ®Google Scholar
• Wang H, Hanash SM. Contributions of proteome profiling to the molecular analysis of cancer. Technol Cancer Res Treat 2002;1(4):237-46
   Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27(45):5904-12
   PubMed Web of Science ®Google Scholar
• Deighton RF, McGregor R, Kemp J, et al. Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 2010;20(4):691-703
   PubMed Web of Science ®Google Scholar
• Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010;73(10):1823-38
   Google Scholar
• Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004;64(7):2496-501
   PubMed Web of Science ®Google Scholar
• Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007;98(2):201-13
   PubMed Web of Science ®Google Scholar
• Chumbalkar VC, Subhashini C, Dhople VM, et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005;5(4):1167-77
   Google Scholar
• Melchior K, Tholey A, Heisel S, et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. J Proteome Res 2009;8(10):4604-14
   Google Scholar
• Polisetty RV, Gautam P, Gupta MK, et al. Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: a grade III malignant glioma. J Proteome Res 2013;12(7):3128-38
   PubMed Web of Science ®Google Scholar
• Kozuka-Hata H, Nasu-Nishimura Y, Koyama-Nasu R, et al. Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome. PLoS One 2012;7(8):e43398
   Google Scholar
• Wolburg H, Noell S, Fallier-Becker P, et al. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 2012;33(5-6):579-89
   PubMed Web of Science ®Google Scholar
• Reynes G, Vila V, Martin M, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011;102(1):35-41
   PubMed Web of Science ®Google Scholar
• Jung CS, Foerch C, Schanzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007;130(Pt 12):3336-41
   PubMed Web of Science ®Google Scholar
• Sreekanthreddy P, Srinivasan H, Kumar DM, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010;19(6):1409-22
   PubMed Web of Science ®Google Scholar
• Kumar DM, Thota B, Shinde SV, et al. Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 2010;9(11):5557-67
   PubMed Web of Science ®Google Scholar
• Petrik V, Saadoun S, Loosemore A, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008;54(4):713-22
   PubMed Web of Science ®Google Scholar
• Zougman A, Pilch B, Podtelejnikov A, et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008;7(1):386-99
   PubMed Web of Science ®Google Scholar
• Schutzer SE, Liu T, Natelson BH, et al. Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010;5(6):e10980
   PubMed Web of Science ®Google Scholar
• Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007;6(2):559-70
   PubMed Web of Science ®Google Scholar
• Ohnishi M, Matsumoto T, Nagashio R, et al. Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 2009;59(11):797-803
   Google Scholar
• Schuhmann MU, Zucht HD, Nassimi R, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 2010;36(2):201-7
   PubMed Web of Science ®Google Scholar
• Zupancic K BA, Herman A, et al. Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach. Radiol Oncol 2014. [ Epub ahead of print]
   Google Scholar
• Formolo CA, Williams R, Gordish-Dressman H, et al. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011;10(7):3149-59
   Google Scholar
• Demory Beckler M, Higginbotham JN, Franklin JL, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 2013;12(2):343-55
   PubMed Web of Science ®Google Scholar
• Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013;110(18):7312-17
   PubMed Web of Science ®Google Scholar
• Silva J, Garcia V, Rodriguez M, et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer 2012;51(4):409-18
   PubMed Web of Science ®Google Scholar
• Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6(12):961-7
   PubMed Web of Science ®Google Scholar
• Geho DH, Liotta LA, Petricoin EF, et al. The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006;10(1):50-5
   Google Scholar
• Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013;14(9):e370-9
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11(4):341-7
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15(19):6002-7
   PubMed Web of Science ®Google Scholar
• Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013;26(7):922-9
   Google Scholar
• Wang Z, Bao Z, Yan W, et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res 2013;32(1):59
   Google Scholar
• Combs SE, Rieken S, Wick W, et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011;6:115
   PubMedGoogle Scholar
• Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20(1):245-54
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20(6):810-17
   PubMed Web of Science ®Google Scholar
• Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5(9):e12548
   PubMed Web of Science ®Google Scholar
• Bambury RM, Morris PG. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Expert Rev Anticancer Ther 2014;1-10; [ Epub ahead of print]
   Google Scholar
• Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics 2012;12(4-5):722-35
   PubMed Web of Science ®Google Scholar
• López E, Madero L, Melén GJ. Clinical proteomics in cancer research. Curr Proteomics 2013;10(2):179-91
   Google Scholar
• Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013;34(7):393-400
   PubMed Web of Science ®Google Scholar
• Boisselier B, Gallego Perez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 2012;79(16):1693-8
   PubMed Web of Science ®Google Scholar
• Balana C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9(4):1461-8
   PubMed Web of Science ®Google Scholar
• Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol 2013;115(1):27-35
   PubMed Web of Science ®Google Scholar
• Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA. Nat Med 2014;20(5):474-5
   PubMed Web of Science ®Google Scholar
• Vos MJ, Postma TJ, Martens F, et al. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res 2004;24(4):2511-14
   PubMed Web of Science ®Google Scholar
• Sampath P, Weaver CE, Sungarian A, et al. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Contr 2004;11(3):174-80
   Google Scholar
• Zheng PP, Hop WC, Sillevis Smitt PA, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res 2005;11(12):4388-92
   PubMedGoogle Scholar
• Elstner A, Stockhammer F, Nguyen-Dobinsky TN, et al. Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncol 2011;102(1):71-80
   PubMed Web of Science ®Google Scholar
• Ilzecka J, Ilzecki M. APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur Cytokine Netw 2006;17(4):276-80
   Google Scholar
• Wrensch M, Wiencke JK, Wiemels J, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66(8):4531-41
   Google Scholar
• Nano R, Capelli E, Argentina F, et al. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours. Cell Mol Biol (Noisy-le-grand) 2003;49(4):525-8
   Google Scholar
• Ammirati M, Rao S, Granger G. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front Biosci 2001;6:B17-24
   Google Scholar
• Alper O, Stetler-Stevenson WG, Harris LN, et al. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 2009;100(9):1748-56
   PubMed Web of Science ®Google Scholar
• Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12(19):5698-704
   PubMed Web of Science ®Google Scholar
• Crocker M, Ashley S, Giddings I, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2011;13(1):99-108
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Hayama M, Adachi A, et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 2008;28(1B):415-18
   Google Scholar
• Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005;65(12):5190-4
   PubMed Web of Science ®Google Scholar
• Taomoto K, Kokunai T, Okuda T, et al. [The value of neuron specific enolase (NSE) in patients with brain tumors]. No To Shinkei 1987;39(2):169-73
   Google Scholar
• Quaranta M, Divella R, Daniele A, et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 2007;93(3):275-80
   PubMed Web of Science ®Google Scholar
• Zheng X, Chang F, Zhang X, et al. G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker. Exp Mol Pathol 2012;93(1):111-15
   Google Scholar
• Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 2009;11(5):468-76
   Google Scholar
• Reddy PS, Umesh S, Thota B, et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 2008;7(5):663-8
   PubMed Web of Science ®Google Scholar
• Todaro L, Christiansen S, Varela M, et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 2007;83(2):135-44
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Mohan SS, Raju R, et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol 2010;11(1):R3
   Google Scholar